Figure S1. miR-606 expression is downregulated in plasma from patients with breast cancer and triple-negative breast cancer cells. (A) Differential expression profile of miR-606 between the plasma of patients with breast cancer and healthy individuals. (B) miR-606 expression levels in MCF10A, T47D, SK-BR-3, MCF7, HS 578T, BT20, MDA-MB-231 and BT549 cells. Data are presented as the mean ± SEM and were analyzed using one-way ANOVA. *P<0.05 and ***P<0.001 vs. MCF10A. miR, microRNA; n.s., not significant.



Figure S2. miR-606 expression in MDA-MB-231 and BT549 cells transfected with miR-606 mimics at 0, 24 and 48 h. Data are presented as the mean ± SEM and were analyzed using one-way ANOVA. **P<0.005 and ***P<0.001. miR, microRNA; ns, not significant.



Figure S3. STC1 mRNA expression levels in various breast cancer cell lines. (A) STC1 expression levels of MCF10A, T47D, SK-BR-3, MCF7, HS 578T, BT20, MDA-MB-231 and BT549 cells. STC1 expression levels in TNBC cells transfected with (B) miR-606 mimics and (C) anti-miR-606, as determined using reverse transcription-quantitative PCR analysis. Data are presented as the mean ± SEM. Data were analyzed using (A) one-way ANOVA and (B and C) Student's t-test. (A) *P<0.05 and ***P<0.001 vs. MCF10A. (B) $^{\$}$P<0.05 and $^{\$\$\$}$P<0.001 vs. Cont. (C) $^{\#}$P<0.05 and $^{\#\#}$P<0.005 vs. anti-Cont. miR, microRNA; n.s., not significant; STC1, Stanniocalcin 1; Cont, control.